Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 350
- Registration Number
- NCT00047138
- Locations
- π©πͺ
Universitaetsklinikum des Saarlandes, Homburg, Germany
π«π·Institut Gustave Roussy, Villejuif, France
π³π±Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00041288
- Locations
- πΊπΈ
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
πΊπΈSimmons Cancer Center - Dallas, Dallas, Texas, United States
πΊπΈUniversity of Missouri Kansas City School of Medicine, Kansas City, Missouri, United States
Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 175
- Registration Number
- NCT00030719
- Locations
- π§πͺ
Universitair Ziekenhuis Gent, Ghent, Belgium
π³π΄Rikshospitalet University Hospital, Oslo, Norway
π¬π§Birmingham Children's Hospital, Birmingham, England, United Kingdom
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 22
- Registration Number
- NCT00003727
- Locations
- πΊπΈ
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT00003194
- Locations
- πΊπΈ
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
πΊπΈChildren's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT00047281
- Locations
- πΊπΈ
Brigham and Women's Hospital, Boston, Massachusetts, United States
πΊπΈMassachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
πΊπΈDana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00052351
- Locations
- πΊπΈ
Center for Cancer Research, Bethesda, Maryland, United States
πΊπΈWarren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 31
- Registration Number
- NCT00002594
- Locations
- πΊπΈ
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
πΊπΈSylvester Cancer Center, University of Miami, Miami, Florida, United States
πΊπΈMiami Children's Hospital, Miami, Florida, United States
Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 11
- Registration Number
- NCT00002943
- Locations
- πΊπΈ
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
- Conditions
- Childhood Mixed Cellularity Classical Hodgkin LymphomaStage I Childhood Hodgkin LymphomaStage IV Childhood Hodgkin LymphomaChildhood Lymphocyte-Depleted Classical Hodgkin LymphomaChildhood Nodular Lymphocyte Predominant Hodgkin LymphomaStage II Childhood Hodgkin LymphomaChildhood Nodular Sclerosis Classical Hodgkin LymphomaStage III Childhood Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1734
- Registration Number
- NCT00025259
- Locations
- πΊπΈ
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
πΊπΈNationwide Children's Hospital, Columbus, Ohio, United States
πΊπΈUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.